El interés en corto de Merit Medical Systems da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Merit Medical Systems. Los datos de interés en corto se actualizan cada dos semanas.

Merit Medical Systems (NASDAQ:MMSI) Bolsa, Informe de interés en corto

MERIT MEDICAL SYSTEMS INC

Merit Medical Systems

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

market, stock market, Investors,Use,Laptops,To,Analyze,Stock,Market,,Investment,Strategies.,And

Pre-Market Outlook

AAPG

KRUS

MMSI

Penguin Solutions, Inc. - Ordinary Shares

PENG

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: PENG, MMSI, SAR, AAPG y KRUS.

5 acciones en el foco este martes: PENG, MMSI, SAR, AAPG y KRUS

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems Inc

Merit Medical Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NYSE">MMSI</a>) short percent of float has fallen 4.05% since its last report. The company recently reported that it has 3.27 million shares sold short, which is 7.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Merit Medical Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751997629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merit Medical Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Merit Medical Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Merit Medical Systems's peer group average for short interest as a percentage of float is 8.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What's Driving the Market Sentiment Around Merit Medical Systems?

WIIM

Merit Medical Systems shares are trading higher after the company announced it appointed a new CEO. Additionally, Needham and Piper Sandler maintained Buy ratings on the stock.

Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) announced a leadership transition on Monday, naming Martha Aronson as its next President and CEO, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46284655/merit-medical-names-martha-aronson-as-new-president-and-chief-executive-officer" rel="noreferrer noopener">effective October 3, 2025</a>.
Current CEO Fred Lampropoulos, who founded the company in 1987, will continue to serve as Chairman of the Board following the transition.
The Utah-based medical technology company also provided early revenue estimates for the second quarter, projecting between $380 million and $384 million in unaudited sales, a year-over-year rise of 12% to 14% compared to the same period in 2024. The analyst consensus estimate is pegged at $372.47 million. Constant currency growth is expected in the range of 11% to 13%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46102914/fda-sounds-alarm-after-33-injuries-tied-to-medtronic-device-malfunction" rel="noreferrer noopener">FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction</a>
Following the announcement, Needham analyst Mike Matson reiterated a buy rating for Merit Medical Systems and maintained a $108 price forecast.
In the first quarter of 2025, Merit Medical Systems <a target="_blank" href="https://www.merit.com/wp-content/uploads/2025/04/MMSI-Q12025-Earnings-PressRelease-FINAL.pdf" rel="noreferrer noopener">delivered</a> a strong performance, with revenue climbing to $355.4 million, up 9.8% from the same period last year. On a constant currency basis, organic growth reached 6%, signaling solid underlying demand across its portfolio.
<h2 class="wp-block-heading">Leadership Change Marks New Chapter</h2>
Aronson brings with her a wealth of experience in international healthcare management. She previously held executive roles at companies like Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) and Hill-Rom Holdings Inc., and spent nearly two decades in leadership positions at Medtronic plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).
She currently serves on the board of CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) and has held directorships at several other medical and tech firms. Lead Independent Director Dr. F. Ann Millner said the board was united in choosing Aronson after an exhaustive selection process.
Price Action: MMSI shares are trading higher by 2.12% to $93.05 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/07/46289610/palantir-co-founder-joe-lonsdale-wants-a-fda-overhaul-with-special-forces-style-ai-team-because-china-is-racing-to-outpace-us-in-biotech" target="_blank" rel="noreferrer noopener">Palantir Co-Founder Joe Lonsdale Wants A FDA Overhaul With Special Forces-Style AI Team Because China Is Racing To Outpace US In Biotech</a></li>
</ul>
Photo by PeopleImages.com &#8211; Yuri A via Shutterstock

Equities

News

Health Care

Markets

Movers

General

CNMD

Merit Medical Names Medtronic Veteran Martha Aronson As Next CEO, Projects Strong Outlook

In the latest quarter, 14 analysts provided ratings for Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $108.0, a high estimate of $112.00, and a low estimate of $100.00. This current average represents a 2.83% decrease from the previous average price target of $111.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1751976086_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Merit Medical Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Merit Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Merit Medical Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.84%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.48%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Merit Medical Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 14 Analyst Ratings Have To Say About Merit Medical Systems

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $108 price target.

Price Target

Reiteration

Needham Reiterates Buy on Merit Medical Systems, Maintains $108 Price Target

U.S. stock futures were fluctuating on Tuesday after trimming gains from their records on Monday. Futures of major benchmark indices were trading mixed.
President Donald Trump announced sweeping <a href="https://www.benzinga.com/markets/equities/25/07/46281204/wall-street-today-trump-tariffs-japan-south-korea-stocks-drop">25% tariffs</a> on all imports from Japan and South Korea, and sent letters to a total of 14 countries, all posted on his Truth Social account, starting Aug. 1. 
Japan&#8217;s Prime Minister Shigeru Ishiba has since voiced his <a href="https://www.benzinga.com/markets/economic-data/25/07/46288472/japans-prime-minister-criticizes-trumps-tariff-decision-shigeru-ishiba-calls-move-truly-regrettable">dissatisfaction with Trump's decision</a> to impose 25% tariffs on goods imported from the country, calling it "truly regrettable." 
The 10-year Treasury bond yielded 4.41% and the two-year bond was at 3.90%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 95.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.10%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.08%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.21%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.32%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Tuesday. The SPY was up 0.11% at $621.36, while the QQQ advanced 0.26% to $553.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Monday, consumer staples and utilities stocks defied a broader market downturn, closing higher, while most sectors on the S&amp;P 500 finished in negative territory.
Consumer discretionary, materials, and energy stocks recorded the most significant losses, as U.S. stocks settled lower overall.
In corporate news, Cogent Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) announced positive topline results from Part 2 of the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, demonstrating clinically meaningful and statistically significant improvements across primary and all key secondary endpoints.
Conversely, Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares experienced a decline of around 18% after CoreWeave revealed its intentions to acquire the company in an all-stock deal.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.92%</td>
<td>20,412.52</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.79%</td>
<td>6,229.98</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.94%</td>
<td>44,406.36</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.55%</td>
<td>2,214.23</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
BlackRock shifted its investment focus from traditional macro anchors to &#8220;mega forces&#8221; like AI, believing these will be &#8220;durable drivers of returns in both the near and long term.&#8221;
This tactical change comes as long-term macro stability wanes, yet the firm sees no need to reduce risk. Instead, they view AI-related investments as a &#8220;new anchor for returns,&#8221; bolstered by &#8220;immutable economic laws&#8221; that limit rapid global change.
This strategy keeps BlackRock &#8220;risk on&#8221; and overweight U.S. equities, anticipating solid corporate earnings despite potential growth dents from tariffs or caution.
Louis Navellier of Navellier &amp; Associates said that tariffs are roiling markets again.
&#8220;Tariffs are back on the front burner as the July 9th deadline is upon us. Rumors abound on pending agreements, along with threats if trading partners aren&#8217;t responsive in a timely fashion. But after the first 90-day delay, expectations are that nothing particularly painful will persist for long, and that the saber rattling will continue,&#8221; he said.
Navellier also highlighted that since the date for actual tariff increases has been pushed to Aug. 1st, &#8220;For now, we&#8217;re seeing some modest hedging taking place today, which isn&#8217;t particularly painful given the recent new all-time highs in stocks.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>June&#8217;s NFIB optimism index data will be out by 6:00 a.m. ET.</li>
<li>May&#8217;s consumer credit data will be released by 3:00 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Optical Cable Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) surged 35.64% after announcing the strategic collaboration with Lightera, including an investment by Lightera resulting in a 7.24% ownership stake in OCC. This partnership aims to expand product offerings and integrated cabling solutions, particularly for the data center and enterprise sectors, with OCC handling sales.</li>
<li>BioSig Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) jumped 27.27% following its merger with Streamex, securing up to $1.1 billion in growth financing to become a major public holder of gold bullion and tokenize the $142 trillion commodities market on the blockchain via Streamex&#8217;s RWA platform powered by Solana.</li>
<li>Thumzup Media Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) rose 4.12% after completing a registered direct public offering, raising approximately $6.04 million net by selling non-voting Series C Convertible Preferred Stock, with proceeds allocated for general corporate purposes and ad-tech operations.</li>
<li>Helius Medical Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) dropped 10.69% after reports that it plans to sell up to $25 million in common stock.</li>
<li>Penguin Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) rose 2.01% in premarket on Tuesday as analysts expect it to report earnings of 33 cents per share on the revenue of $328.81 million after the closing bell.</li>
<li>Saratoga Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) was up 0.23% as it is expected to report earnings after market close. Analysts estimate earnings of 93 cents per share on revenue of $32.29 million.</li>
<li>Kura Sushi USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) advanced 1.62% as analysts expect it to report a quarterly loss of 1 cent per share on revenue of $71.83 million after the closing bell.</li>
<li>Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) gained 0.97% after naming Martha Aronson as President and CEO and said it sees preliminary second-quarter revenue of $380 million to $384 million.</li>
<li>Ascentage Pharma Group International ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) was 0.29% above the flatline after naming Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.77% to hover around $67.41 per barrel.
Gold Spot US Dollar fell 0.31% to hover around $3,326.03 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.18% at the 97.3020 level.
Asian markets ended higher on Monday as South Korea's Kospi, India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, Australia's ASX 200, Japan's Nikkei 225, and China&#8217;s CSI 300 indices rose. European markets were also higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here&#8217;s What It Means For Investors</a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

BSGM

COGT

Core Scientific, Inc. - Class A Common Stock

CORZ

HSDT

TZUP

US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns'

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Penguin Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) to post quarterly earnings at 33 cents per share on revenue of $328.81 million after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Penguin Solutions shares gained 0.8% to $21.10 in after-hours trading.</li>
<li>Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) named Martha Aronson as President and CEO and said it sees preliminary second-quarter revenue of $380 million to $384 million. Merit Medical shares gained 4.8% to $95.52 in the after-hours trading session.</li>
<li>Analysts are expecting Saratoga Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) to post quarterly earnings at 93 cents per share on revenue of $32.29 million. Saratoga Investment shares gained 0.2% to $25.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Ascentage Pharma Group International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) named Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Ascentage Pharma shares fell 1.9% to close at $42.04 on Monday.</li>
<li>Analysts expect Kura Sushi USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) to post a quarterly loss of 1 cent per share on revenue of $71.83 million. Kura Sushi shares fell 5.4% to close at $85.88 on Monday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46271576/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-8">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo courtesy: Thapana_Studio via Shutterstock

Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday

Guidance

Merit Medical Sees Prelim. Q2 Revenue $380M-$384M

Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors
Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025

Management

Merit Medical Names Martha Aronson As President And CEO

Merit Medical Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NYSE">MMSI</a>) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 3.15 million shares sold short, which is 7.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Merit Medical Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749488419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merit Medical Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Merit Medical Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Merit Medical Systems's peer group average for short interest as a percentage of float is 7.52%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Merit Medical Systems?

Fred Lampropoulos, President and CEO at Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), disclosed an insider sell on June 3, according to a recent SEC filing.
What Happened: Lampropoulos's decision to sell 10,000 shares of Merit Medical Systems was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000856982/000141588925015447//Archives/edgar/data/856982/000141588925015447/0001415889-25-015447-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $951,200.
The latest market snapshot at Wednesday morning reveals Merit Medical Systems shares down by 0.0%, trading at $94.6.
<h3>About Merit Medical Systems</h3>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Financial Milestones: Merit Medical Systems's Journey</h3>
Revenue Growth: Merit Medical Systems's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 9.84%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 48.41%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Merit Medical Systems's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.51.
</li>
</ul>
Debt Management: Merit Medical Systems's debt-to-equity ratio is below the industry average at 0.57, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 46.37, Merit Medical Systems's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.09 is above industry norms, reflecting an elevated valuation for Merit Medical Systems's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 19.8, Merit Medical Systems demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000856982">Check Out The Full List Of Merit Medical Systems's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

President and CEO At Merit Medical Systems Sells $951K Of Stock

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) has outperformed the market over the past 20 years by 1.28% on an annualized basis producing an average annual return of 9.54%. Currently, Merit Medical Systems has a market capitalization of $5.58 billion. 
Buying $1000 In MMSI: If an investor had bought $1000 of MMSI stock 20 years ago, it would be worth $6,363.21 today based on a price of $94.43 for MMSI at the time of writing.
<h3>Merit Medical Systems's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748465111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Merit Medical Systems 20 Years Ago Would Be Worth Today

Piper Sandler analyst Jason Bednar maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and raises the price target from $106 to $110.

Piper Sandler Maintains Overweight on Merit Medical Systems, Raises Price Target to $110

Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $108 to $112.

Canaccord Genuity Maintains Buy on Merit Medical Systems, Raises Price Target to $112

Wells Fargo analyst Larry Biegelsen maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and raises the price target from $106 to $108.

Wells Fargo Maintains Overweight on Merit Medical Systems, Raises Price Target to $108

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) lowers FY2025 Adj EPS guidance from $3.29-$3.42 to $3.28-$3.41 vs $3.65 analyst estimate. Raises FY2025 sales outlook from $1.47 billion-$1.49 billion to $1.48 billion-$1.50 billion vs $1.48 billion estimate.

Merit Medical Systems Lowers FY2025 Adj EPS Guidance from $3.29-$3.42 to $3.28-$3.41 vs $3.65 Est; Raises FY2025 Sales Guidance from $1.47B-$1.49B to $1.48B-$1.50B vs $1.48B Est

Merit's updated full-year 2025 financial guidance now reflects the projected impacts of the Biolife acquisition from the merger effective date of May 20, 2025 through December 31, 2025. Merit is otherwise reaffirming prior full-year 2025 financial guidance previously announced on April 24, 2025.

Merit Medical Systems Now Sees FY25 Net Sales Of $1.480B - $1.501B Vs Prior Guidance Range Of $1.470B - $1.490B; Now Expects FY25 Non-GAAP EPS Of $3.28-$3.41 Vs Prior Outlook Of $3.29-$3.42

<ul>
<li>Acquired business offers the StatSeal&#xAE; and WoundSeal&#xAE; products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.</li>
<li>Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile</li>
<li>Merit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acquisition</li>
</ul>
Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. ("Biolife") in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal.
The aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately $120 million. This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance.

Merit Medical Systems Acquires Biolife Delaware In $120M Merger Transaction

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 13.27%. Currently, Merit Medical Systems has a market capitalization of $5.84 billion. 
Buying $1000 In MMSI: If an investor had bought $1000 of MMSI stock 15 years ago, it would be worth $6,432.79 today based on a price of $98.83 for MMSI at the time of writing.
<h3>Merit Medical Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747666815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Merit Medical Systems Stock In The Last 15 Years

Press Releases

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD

Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025

Merit Medical Launches the Ventrax™ Delivery System

Earnings

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

Comments

Merit Medical Systems

Interés en corto

Merit Medical Systems (NASDAQ:MMSI) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL